Sign In
Buy VIR
$8.77
+0.0300 (+0.343%)
At Close: Jun 03, 2026
Defiance ETFs: A Revolution In Thematic ETF Investing (Podcast Transcript)
04:23am, Monday, 29'th Mar 2021
Defiance ETFs: A Revolution In Thematic ETF Investing (Podcast Transcript)
GlaxoSmithKline, Vir Biotechnology Seek Emergency FDA Authorization For COVID-19 Drug
12:42pm, Friday, 26'th Mar 2021
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc. (NASDAQ: VIR) have submitted an application to the Food and Drug Administration requesting emergency use authorization for VIR-7831, an inve
GlaxoSmithKline and Vir Biotech seek FDA emergency authorization for COVID antibody treatment
08:40am, Friday, 26'th Mar 2021
GlaxoSmithKline PLC and Vir Biotechnology Inc. said Friday they have submitted to the U.S. Food and Drug Administration an application for emergency use authorization for their antibody treatment for
LONDON and SAN FRANCISCO, March 26, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the submission of an application to the U.S.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR
01:03am, Wednesday, 24'th Mar 2021
NEW YORK, March 24, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or the "Company") (NASDAQ: VIR). Such investors are advi
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR
10:29pm, Sunday, 21'st Mar 2021
New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or the "Company") (NASDAQ: VIR). Such investors a
Here's Why Clinical-Stage Biotechs Get Hit Harder During a Market Decline
01:00pm, Sunday, 21'st Mar 2021
Short-term investors may not see the long-term potential.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR
05:13pm, Thursday, 18'th Mar 2021
NEW YORK, March 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or the "Company") (NASDAQ: VIR). Such investors are advi
Alnylam, Vir Biotech Deprioritize COVID-19 Drug Development In Hushed Manner
11:47am, Wednesday, 17'th Mar 2021
Last week, Vir Biotechnology Inc's (NASDAQ: VIR) and its collaborating partner GlaxoSmithKline Plc (NYSE: GSK) announced interim Phase 3 data from COVID-19 antibody therapy, named VIR-7831 (GS
Defiance ETFs: A Revolution In Thematic ETF Investing (Podcast)
11:00am, Wednesday, 17'th Mar 2021
Defiance ETFs: A Revolution In Thematic ETF Investing (Podcast)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR
09:21pm, Sunday, 14'th Mar 2021
New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or the "Company") (NASDAQ: VIR). Such investors a
Vir Biotechnology, Inc. (VIR) Surges 32.1%: Is This an Indication of Further Gains?
08:44am, Friday, 12'th Mar 2021
Vir Biotechnology, Inc. (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be m
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR
06:20am, Friday, 12'th Mar 2021
NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or the "Company") (NASDAQ: VIR). Such investors are adv
Why Vir Biotechnology Stock Soared Today
05:12pm, Thursday, 11'th Mar 2021
Investors are excited about the potential of the company's investigational coronavirus therapy.
VIR Biotech CEO on its positive Covid antibody drug results
11:34am, Thursday, 11'th Mar 2021
CNBC's Meg Tirrell discusses VIR Biotechnology's antibody drug results and what it can do to aid the Covid pandemic with VIR Biotech CEO George Scangos.
